EGYPT – Alexandria Company for Pharmaceuticals and Chemical Industries has reported a 19.6% year-on-year (YoY) increase in its net profit after tax in the first 11 months of the fiscal year (FY) 2022/2023, from July 1st, 2022 to May 31st, 2023.
According to a recent regulatory filing, revenues came in at EGP 1.416 billion (US$46 million) from July 2022 through May 2023, up 40% year-on-year from EGP 1.012 billion (US$33 million) during the same months in the prior year.
Alexandria Company for Pharmaceuticals and Chemical Industries is an affiliated company of Drug Holding Company (Holdipharma).
The Egypt-based company is engaged in the manufacture, development, and marketing of pharmaceutical, chemical, veterinary, and nutritional food products.
Additionally, the company manufactures, develops, and markets medical appliances such as adhesive plasters, dental cartridges, medicated adhesive tapes, sterile gauze dressing, and surgical gloves.
Alexandria Company for Pharmaceuticals and Chemical Industries posted a net profit of EGP 148.930 million (US$4.84 million) in the first 11 months of the FY 2022/23, witnessing a growth of 19.6% from EGP 124.533 million (US$4.04 million) in the corresponding period of the last fiscal year.
Comparably, the company posted a 34.68% year-on-year increase in net profit after tax in the first nine months of FY 2022/2023.
The company’s net profit after tax jumped to EGP 108.222 million (US$3.51 million) in the nine-month period ended March 31st, 2023 from EGP 80.357 million (US$2.61 million) in the year-ago period.
In the past 11 months, Alexandria Company for Pharmaceuticals and Chemical Industries has reported strong growth and profitability driven by robust investments while maintaining a favorable share structure.
Its portfolio includes more than 185 products, covering most of the therapeutic areas, including anesthetics, Dental anesthetics, local analgesics, Respiratory, Gastrointestinal, ophthalmic, and cardiovascular drugs. gastrointestinal, genitourinary, and respiratory drugs.
Alexandria Company for Pharmaceuticals and Chemical Industries has a huge production capacity and operates two main factories with an average production capacity of 250,000 packs per day.
The company is set to announce its July-September quarter results for the current fiscal in the coming weeks after the launch of new production lines for disinfectant products.
The new line has a production capacity of 7 million carpules per month, increasing the company’s total production capacity to 11 million carpules per month.
The production line for dental anesthetic carpules of Alexandria Company for Pharmaceuticals and Chemical Industries was set up at an investment of 45 million Egyptian pounds (up to US$1.5 million).
This venture will build on the government’s ongoing efforts targeting self-sufficiency in vital medical supplies, alongside supporting the private sector and maximizing its role in development processes.
In line with its commitment to impacting people’s lives through innovative products, Alexandria Company for Pharmaceuticals and Chemical Industries is looking to establish a new line for producing pre-packed anesthetic syringes.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
